Sequent Scientific Limited , a prominent player in the pharmaceuticals sector, has taken another significant step to enhance employee engagement and ownership. The company's Nomination and Remuneration Committee has approved the allotment of 11,63,301 equity shares under its Employee Stock Option Plan 2020 (SeQuent ESOP 2020).

Latest Allotment Details

The committee approved the latest share allotment through a resolution passed by circulation, demonstrating the company's commitment to swift decision-making while adhering to corporate governance norms.

Updated Share Capital Structure

The allotment has resulted in a further increase in the company's paid-up equity share capital, building upon previous ESOP allotments:

Strategic Significance

This equity share allotment under the ESOP scheme continues to serve multiple strategic purposes for Sequent Scientific:

Employee Retention and Motivation: By offering stock options, the company aims to retain key talent and align employee interests with long-term organizational goals. The ESOP acts as a powerful incentive for employees to contribute to the company's growth and success.

Wealth Creation Opportunity: The scheme provides employees with an opportunity to benefit from the company's potential future growth and share price appreciation, fostering a culture of ownership.

Equity Rights and Compliance

The newly allotted shares will rank pari-passu with the existing equity shares of the company, ensuring equal rights in terms of voting and dividends as previously issued shares. This maintains equity among all shareholders while expanding the employee ownership base.

Market Position

As a mid-cap company in the pharmaceuticals sector with a market capitalization of ₹5,467.50 crores, Sequent Scientific continues to strengthen its position through strategic employee engagement initiatives. The company's focus on fostering shared success among its workforce reflects its commitment to sustainable growth in the competitive life sciences market.

Sequent Scientific Limited , a prominent player in the life sciences sector, has successfully completed its postal ballot process for a significant corporate transformation. The company's shareholders have overwhelmingly approved the proposed name change and related corporate actions through remote e-voting.

Postal Ballot Results and Shareholder Approval

The postal ballot voting concluded on December 28, 2025, with shareholders demonstrating strong support for the proposed changes. The voting results show exceptional approval rates across both resolutions:

Key Approved Resolutions

Shareholders approved two special resolutions through the postal ballot process:

Resolution 1: Change of company name from 'Sequent Scientific Limited' to 'Viyash Scientific Limited' along with consequential alterations in the Memorandum of Association and Articles of Association.

Resolution 2: Alteration of the Objects Clause of the Memorandum of Association to align with the company's strategic direction.

Voting Participation and Process

The postal ballot process witnessed significant participation from various shareholder categories:

The e-voting process was conducted through the National Securities Depository Limited (NSDL) platform, ensuring transparency and accessibility for all eligible shareholders.

Corporate Transformation Timeline

The postal ballot notice was dispatched on November 28, 2025, following the board's earlier approval of the name change proposal. The remote e-voting period commenced on November 29, 2025, and concluded on December 28, 2025. The resolutions are deemed to have been passed on the last date of remote e-voting.

Strategic Implications

This approval marks a significant milestone in Sequent Scientific's corporate evolution, as the company transitions to the 'Viyash Scientific Limited' identity. The name change reflects the company's strategic alignment with the Viyash brand and supports its positioning in the life sciences sector. The alteration of the Objects Clause provides the company with enhanced flexibility to pursue its business objectives under the new corporate structure.